USA    |    Global :  English    简中    繁中    |    MAP
  Login    |     Shopping Cart
 
About CytoTest
  Company Overview
  Management Team
  News & Events
  Distributors
  Business Opportunities
  Job Opportunity
  Contact CytoTest
 
  Management Team

 

 Chief Scientific Officer - Reinhard Ebner 

 

Reinhard Ebner has been a research manager and senior investigator for over 30 years. He has wide scientific, technical and strategic experience, in both academic and corporate settings, with broad knowledge of modern biology and the pharmaceutical and bio-technology industry, and a recent focus in contemporary oncology and translational medicine, and a documented record of discoveries leading to novel therapies in the clinic and on the market.

He has extensive hands-on experience with, and documented record of achievements in, target and marker discovery, assay development, high-throughput screening, signal transduction and pathway delineation, lead optimization and development, and proven expertise in solving complex questions in molecular and cell biology, particularly as they relate to disease mechanism and drug discovery. 

Biography:

Having served as a research manager and senior investigator in both academic and corporate settings, Dr. Reinhard Ebner has extensive scientific, technical and strategy experience, combined with a broad knowledge of modern biology and the biomedical and biotechnology industry, with a recent focus in contemporary oncology, translational medicine and molecular diagnostics.

He received his undergraduate degree in Biology from the University of Regensburg and his doctorate in Microbiology and Genetics from the University of Osnabrück, Germany, where he then served on the faculty of the Genetics department.

In 1989, Dr. Ebner was awarded a research fellowship to work as a visiting scientific specialist at Genentech, Inc. in San Francisco. There, he identified and cloned the long elusive first type I TGF-ß receptor. He was first to show TGFß-induced epithelial-mesenchymal-transitions (EMTs) in cells in culture and, in the years following, made a series of substantial contributions to the fields of cytokine biology, receptor-ligand interactions and intracellular trafficking, cell differentiation, early development and tissue repair, first at Genentech and then at the University of California, San Francisco and at Stanford University Medical School.

After moving to Human Genome Sciences in 1995, Dr. Ebner became one of the most productive novel gene finders there and the inventor of all the HGS targets now in clinical trials and discovered many other important proteins around which HGS established pre-clinical and clinical development programs, including such molecules as DR4, the first and long sought after receptor for the cytotoxic ligand TRAIL, as well as LIGHT, IL-17B and its receptor, BlyS and TR6. In 2000, he joined Avalon Pharmaceuticals – hired as the first scientist following the company founders, where he was instrumental in the initiation of intramural and external research programs and contributed to corporate and scientific infrastructure development, working predominantly in the fields of chemical genomics, cancer research, data mining and HTS assay development. He also coordinated the company’s therapeutic antibody target discovery alliances and has a long-standing interest in alternative and novel drug discovery paradigms and development strategies.

Dr. Ebner is a frequently invited plenary speaker at national and international conferences and member of several scientific advisory panels and has served on state and national study sections. He has authored nearly 100 original research publications, with several thousand citations by others. He is a recipient of grant and manuscript peer review service awards and society memberships, an ad hoc reviewer and editor for scientific journals, has over 50 issued US patents and is the primary inventor on more than 800 patent applications world wide. Several of his discoveries have led to new therapeutics now in the clinic or on the market.

Dr. Ebner has been involved with the National Cancer Institute for many years, and is currently a research adviser in its cancer genomics section. He also is a consultant to various biotech companies, and serves as the CSO of CytoTest Inc., a provider of innovative molecular diagnostic solutions.

 

 

 

CytoTest Inc.  |  9430 Key West Avenue, Suite 210, Rockville, MD 20850, USA
Tel:1-855-CYTOTEST  |  +1-202-688-1188  |  sales@cytotest.com

© 2013 CytoTest Inc. All Rights Reserved.
Website Design | Youhome